Patent Baristas

Lewis & Clark Law Review’s latest issue and it features a business forum on the Supreme Court’s recent patent decision in KSR v. Teleflex. If you want to talk KSR, this is your stop.  There are eleven action-packed articles related to this decision and this is a great way to get your fill of opinions. […]

Generic drug maker Mylan got some good news from the U.S. Court of Appeals for the Federal Circuit in a patent litigation related to its heartburn treatment Omeprazole, the generic version of British drug maker AstraZeneca’s Prilosec, when the court affirmed a District Court ruling that Mylan’s 10 mg and 20 mg Omeprazole delayed-release capsules […]

The U.S. Court of Appeals for the Federal Circuit looked at the issue of whether Aventis committed that most horrible of patent sins — inequitable conduct before the United States Patent and Trademark Office (PTO).   Aventis Pharma v. Amphastar and Teva (07-1280) . Earlier, the CAFC held that the dosage of the prior art composition […]

MedImmune and Genentech have announced that they reached a settlement regarding their patent lawsuit over MedImmune’s best-selling drug Synagis®, which is used to prevent respiratory infections in infants.  “The parties advise the court that they have reached a settlement,” according to a telephone conference recorded on the docket in the U.S. District Court for the […]

Ortho-McNeil kept it’s exclusivity on topiramate after a district court blocked Mylan Labs from infringing Ortho-McNeil’s U.S. Patent No. 4,513,006 covering Topomax® (topiramate), an anticonvulsive drug used to treat epilepsy. The trial court also reset the effective approval date for Mylan’s Abbreviated New Drug Application (ANDA). The United States Court of Appeals for the Federal […]

Forest Labs had a bit of a reversal of fortune in its patent dispute with Caraco Pharmaceutical Labs over its drug Lexapro®, which is used to treat depression and generalized anxiety disorder. The U.S. Court of Appeals for the Federal Circuit reversed and remanded the case back to the U.S. District Court, which had dismissed […]

Eighteen states and the District of Columbia have filed suit against Abbott Laboratories and Solvay’s Fournier Industrie et Santé and Laboratories Fournier for allegedly entering into a scheme to block the generic version of the cholesterol lowering drug TriCor®  (fenofibrate), indicated for the treatment of hypercholesterolemia and hypertriglyceridemia. According to the AGs in the states, […]

The University of California and Abbott appealed after the district court turned down their attempt to stop Dako from making and selling its HER2 FISH pharmDXTM kit, allegedly infringing U.S. Patents 5,447,841 and 6,596,479.   The Regents of the University Of California, Abbott Labs v. Dakocytomation California (06-1334, -1452; 07-1202) The inventions claimed in the patents are […]